What Нейромет treats: main uses and benefits

Нейромет (ethylmethylhydroxypyridine succinate) is commonly used across conditions presenting with acute episodes that involve systemic or localized discomfort, in contexts involving symptoms related to heightened physiological activity. Its therapeutic application is considered relevant in scenarios involving acute functional stress.

It is often used during phases when symptoms become more noticeable, relevant in contexts involving symptoms linked to organ-specific functional stress in conditions such as acute cerebrovascular accident, chronic cerebral ischemia, dyscirculatory encephalopathy, and mild cognitive impairment. It may assist with symptoms related to physical discomfort and symptoms related to systemic imbalance. Generally, the compound may be part of symptomatic management, applied across domains where additional symptomatic support is needed in managing anxiety disorders, supporting patients during alcohol withdrawal syndrome, and addressing acute intoxication with antipsychotic agents. This supportive relief contributes to easing the overall symptom burden and assists with maintaining functional stability during symptomatic periods.

---

Quick Fact: Relevant for Symptoms that Interfere with Daily Functioning

Regulatory References

1. Google Patents record for the drug's composition

Нейромет (Idebenone) is subject to specific regulatory guidelines that determine which patient populations are eligible to use the medicine for its approved indication. All eligibility rules are based strictly on official regulatory documentation.

Populations for Whom Use is Restricted or Prohibited

Contraindicated Populations:

Use of the medicine is strictly prohibited (contraindicated) for patients with a known hypersensitivity to the active substance, Idebenone, or to any of the excipients in the formulation. The medicine is also contraindicated in individuals with rare hereditary problems, including galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption, due to the presence of lactose as an excipient.

Age and Conditional Use:

The medicine is officially approved for use in adolescent and adult patients 12 years of age and over. Safety and efficacy have not been established in the pediatric population under 12 years.

Patients with hepatic impairment (liver) or renal impairment (kidney) should use the medicine with caution, as clinical data for these populations is limited. For women who are pregnant, use is conditional and requires a formal assessment to ensure the potential therapeutic benefit outweighs any potential risk. For women who are breastfeeding, the regulatory requirement is to either discontinue the medicine or discontinue breastfeeding during treatment.

Interactions with other medicines and products

Нейромет has been documented to cause drug-drug interactions, primarily through its effect as an inducer of certain drug-metabolizing enzymes and transporters in the body. This induction mechanism increases the rate at which other medications are broken down, potentially leading to lower levels of the co-administered drug in the bloodstream.

Key Pharmacokinetic Interactions

• Enzyme and Transporter Induction: Нейромет is a known inducer of the Cytochrome P450 3A4 (CYP3A4) enzyme and the P-glycoprotein (P-gp) drug transporter. Since many medicines are substrates for CYP3A4 and/or P-gp, combining them with Нейромет may significantly reduce their systemic exposure and therapeutic effect.
• Hormonal Contraceptives: Concomitant use with combined hormonal oral contraceptives (such as those containing ethinylestradiol and norgestimate) can lead to a clinically significant decrease in contraceptive hormone concentrations. This interaction may result in contraceptive failure (unintended pregnancy).

Interaction Classification Summary

Mechanism	Affected Drug Categories	Clinical Relevance
CYP3A4/P-gp Induction	Substrates of CYP3A4 and P-gp	Clinically Significant
Decreased Systemic Exposure	Combined Oral Contraceptives	Risk of Therapeutic Failure

It has been shown that Нейромет does not have a clinically significant effect on the metabolism of S-Warfarin, a probe substrate for the CYP2C9 enzyme. Any decision to use Нейромет alongside other medications should be made with careful consideration of its induction capacity to prevent a reduction in the efficacy of the co-administered drugs.

Restoring Mitochondrial Bioenergetics

Idebenone functions as an auxiliary electron carrier in the Mitochondrial Electron Transport Chain (ETC), specifically bypassing deficient Complex I and donating electrons to Complex III (Ubiquinol:cytochrome c oxidoreductase). This action sustains the necessary proton gradient required for ATP synthesis and maintains the membrane potential necessary for cellular function under energetic constraint, influencing the metabolic rate of tissues with high energy demand, such as neuronal and retinal cells.

---

Modulation of Oxidative Stress Pathways

Idebenone and its active metabolite, Idebenol, function as free radical scavengers that neutralize Reactive Oxygen Species (ROS), thereby limiting the chain reaction of lipid peroxidation. This mechanistic cascade results in the stabilization of cell membranes and mitochondrial integrity, acting as a modulator against the activation of the destructive intrinsic apoptosis pathway in cells experiencing metabolic stress. The overall effect is a dual physiological modulation of cellular energy supply and defense mechanisms.

How to Use Нейромет

This section describes the administration and dosing patterns for the active substance and does not constitute medical advice or therapeutic claims.

---

Administration Guidelines

Нейромет, which contains the active substance Idebenone, is designed for the oral route of administration in the form of a 150 mg film-coated tablet. The prescribed regimen establishes a total daily dose of 900 mg for adults and adolescents who are 12 years of age and older.

This total dose is divided into three separate administrations throughout the day. The protocol specifies that each of the three doses be taken with food, as this timing aids the body in absorbing the active ingredient properly.

Administration and Procedural Rules

Procedural Requirement	Instruction
Dosing Frequency	Three times per day (t.i.d.).
Tablet Handling	Tablets must be swallowed whole with water and must not be broken or chewed.
Clinical Oversight	Treatment must be initiated and supervised by a physician experienced in the specific condition.
Population Dose Rules	No specific dose adjustment is required for older adults.

Duration and Protocol

The treatment protocol specifies continuous daily use. The overall use of the medicine, including adjustments for specific populations such as those with hepatic or renal impairment, is managed under the direct supervision of the prescribing specialist.

Research evidence / Overview of studies for Нейромет (Idebenone)

The clinical evaluation of Idebenone has focused primarily on its use in specific, rare conditions where mitochondrial function is part of the disease characteristics, complemented by research evaluating its use in select neurological conditions involving cognitive assessments. The evidence is derived from different types of studies, including controlled trials and large observational programs.

---

Evidence for Visual Function in Leber's Hereditary Optic Neuropathy (LHON)

Research for LHON has included randomized, placebo-controlled trials as well as long-term, open-label programs that monitored patient data over extended periods. Studies monitored changes in vision by measuring Visual Acuity (VA) and color contrast sensitivity, typically during the dynamic or subacute phase of the condition.

Some studies reported changes in visual assessment measures; however, the primary endpoints of the initial controlled trials were not met. Research highlights changes measured during the study period, but evidence is limited regarding the durability of the visual outcomes that were recorded in the studies. Findings indicate that outcomes appear to be influenced by the specific mtDNA mutation a patient carries and the time since symptom onset when research began. Long-term outcomes remain uncharacterized in controlled settings.

---

Evidence for Cardiac Assessment in Friedreich's Ataxia (FA)

Idebenone was evaluated in short-term randomized, double-blind, placebo-controlled trials for its potential use in children and young adults with genetically confirmed Friedreich's Ataxia (FA) who had signs of cardiac hypertrophy. These studies monitored outcomes related to specific cardiac parameters, such as Left Ventricular Mass (LVM), using echocardiography.

Studies report how heart structure evolved over defined time intervals. However, research that examined changes in neurological symptoms during these same studies reported mixed findings that were not consistently associated with the cardiac structure assessments. Comparative evidence is lacking against standard supportive therapy for FA. Sample sizes were modest in the core controlled trials.

---

Evidence for Cognitive Support Across Neurological Conditions

Research has explored the use of Idebenone in studies involving cognitive assessments for conditions like post-stroke status and age-related changes such as Mild Cognitive Impairment (MCI). Studies used scales like the Mini-Mental State Examination (MMSE) and the Montreal Cognitive Assessment (MoCA).

Research describes patterns related to short-term measurements, with some observational data recording changes in global cognitive scores. However, in larger controlled trials focusing on specific disorders, studies often reported findings where the measurements on key cognitive assessments were similar between groups. A major limitation is that a significant portion of the evidence is observational, inherently lacking a control group for comparison.

Common questions about Нейромет (FAQ)

Q: What are the main conditions Нейромет is used for?

According to official regulatory information, the medicine Нейромет (Idebenone) is indicated for the treatment of visual impairment in adolescent and adult patients aged 12 years and older who have Leber's Hereditary Optic Neuropathy (LHON). Its approval is based on the evidence available for this specific rare, genetic visual condition.

Q: Can Нейромет help with symptoms of cognitive decline in older people?

The currently approved use of Нейромет is only for treating visual impairment related to LHON. Although the drug has been investigated for potential benefits in cognitive disorders, official marketing approval for those purposes was not granted in various regions due to clinical data being insufficient or inconsistent for broader indications.

Q: Does Нейромет affect energy levels or cause fatigue?

Official regulatory documents and safety tables for Idebenone list common and uncommon side effects, but fatigue is generally not explicitly listed among the most frequently reported adverse reactions. The medicine's primary mechanism involves supporting cellular energy generation, but this does not necessarily translate into a noticeable change in a person's perceived energy levels.

Q: Does Нейромет have neuroprotective properties?

Yes, official pharmacodynamic information describes Idebenone as an anti-oxidant. Its mechanism of action involves reducing harmful free radicals, a process that is thought to limit oxidative damage and potentially preserve cellular integrity, supporting its use in LHON.

Q: Can older adults expect different side effects from Нейромет compared to younger adults?

Official prescribing information states that no specific dose adjustment is required for older adults (geriatric patients). The safety profile observed in clinical trials was generally comparable between the older adult population and the younger adult study groups.

Q: Does Нейромет cause any issues with driving or operating machinery?

The official product information states that Нейромет has no or negligible influence on a person's ability to drive and use machines. However, if any side effects that could affect concentration or reaction time occur, it is important to discuss these symptoms with your healthcare provider.

Q: Can Нейромет affect my sleep patterns?

Changes in sleep patterns, such as insomnia or altered sleep quality, are not listed as a specific adverse reaction in the key regulatory safety tables. Side effects like dizziness or sleepiness (somnolence) are not listed as common side effects in the official safety documents.

Q: Does Нейромет come in different forms (e.g., tablet, syrup, injection)?

The officially approved formulation of Нейромет containing Idebenone is a 150 mg film-coated tablet for oral use. It is not currently approved or distributed as a syrup or injectable solution.

Q: How frequently is monitoring needed while on Нейромет treatment?

Нейромет is subject to additional monitoring by regulatory agencies. A specialist managing the treatment will determine the necessary frequency of check-ups and monitoring based on the clinical needs and specific condition of the patient.

Q: Is there a specific diet recommended while taking Нейромет?

Yes, regulatory instructions require the medicine to be administered with food. This administrative instruction is in place because taking the medicine with food helps the body properly absorb the active ingredient, Idebenone.

Q: How should I store and dispose of my expired or unused Нейромет?

The medicine should be stored in its original container, out of the sight and reach of children. Official guidelines mandate that you do not dispose of any unused or expired medicine via wastewater or household waste. Consult your pharmacist for the appropriate disposal method based on local requirements.

Q: What is the half-life of Нейромет in the human body?

Data from pharmacokinetic studies indicate that the active metabolites of Idebenone have a plasma half-life of approximately 4 to 7 hours. This refers to the time needed for the amount of the drug's metabolites in the plasma to decrease by half.

Q: Is it normal to experience agitation or nervousness while taking Нейромет?

Agitation or nervousness are not listed among the commonly reported side effects in the official regulatory safety profile tables for this product. Any concerning or severe mood changes that occur should be brought to the attention of the prescribing specialist for review.

Official Storage and Disposal Instructions

The storage and disposal instructions for Idebenone (the active substance in Нейромет) are strictly defined by regulatory labeling to ensure product stability and safety.

Storage Requirements

The medicine must be stored at a temperature not above 30 C. It must not be refrigerated or frozen. To protect the integrity of the tablets, the product must be kept in its original container with the cap tightly closed to protect from moisture. This container must be stored out of the sight and reach of children to prevent accidental ingestion.

Disposal Rules

Any unused or expired medicinal product or waste material should be disposed of in accordance with local requirements. The medicine must not be thrown away via wastewater or household waste.